The protective effect of rheumatic disease agents in COVID-19

Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF...

Descripción completa

Detalles Bibliográficos
Autores principales: Valenzuela-Almada, María O., Putman, Michael S., Duarte-García, Alí
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
3
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833968/
https://www.ncbi.nlm.nih.gov/pubmed/33526326
http://dx.doi.org/10.1016/j.berh.2021.101659
Descripción
Sumario:Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-α) inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials (RCTs) are ongoing to determine the role of other immunosuppressants.

Ejemplares similares